Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million

Velan Capital Investment Management trimmed its Mineralys Therapeutics stake by 140,000 shares in Q1, an estimated $4.11 million sale that left it with 11,000 shares worth $297,990 at quarter-end. The position’s value fell by $5.18 million overall, and Mineralys now represents just 0.19% of the fund’s AUM, outside its top five holdings. The move is notable given Mineralys’ FDA review of lorundrostat, but the article is primarily a routine 13F-style position update.

Analysis

The trim reads less like a negative fundamental call on Mineralys and more like de-risking into a binary event. When a fund takes a position from meaningful to token size before an FDA decision, the market often interprets it as conviction being replaced by event optionality; that can suppress incremental institutional sponsorship even if the story remains intact. The second-order effect is that the stock becomes more tradeable on headline volatility than on underlying science, which tends to widen realized swings into the catalyst window.

The biggest winner from this setup is not necessarily a named competitor, but the broader hypertension late-stage cohort: any weakness in MLYS can rotate capital toward alternative mechanisms with cleaner data or nearer-term commercialization paths. AZN remains the relevant competitive benchmark because its disappointment helped validate the market’s desire for a differentiated aldosterone-synthase thesis; if MLYS wins approval, it strengthens the class, but if the label is narrow or safety language is restrictive, the read-through will be that the market is still overpaying for “best-in-class” optionality.

The main risk is not pre-approval cash burn; it’s post-decision commercialization math. A positive FDA outcome can still be a stock disappointment if the label limits combination use, payers push back on pricing in a crowded antihypertensive market, or launch uptake proves slower than the current embedded valuation assumes. Conversely, a delay or CRL would likely be punished harder than the 12/22 date suggests because the current setup leaves little room for patience once event premium decays.

Consensus seems to be treating this as a clean binary on approval probability, but the more important variable is whether the market has underappreciated the difference between approval and a commercially meaningful label. That makes the stock less attractive as a standalone long into the decision than as a volatility expression around the event. In our view, the asymmetry is better harvested with defined-risk structures rather than outright exposure.

Key Decisions for Investors

• MLYS: avoid initiating a naked long into the FDA date; if holding, reduce size into strength and re-enter only on a pullback or post-decision clarity, because the setup is now dominated by event premium decay rather than fundamentals.
• MLYS Jan-2027 puts or put spreads: use as a defined-risk hedge against approval disappointment, label restriction, or launch skepticism; best risk/reward if implied volatility softens after the event window starts pricing in.
• Pair trade: long AZN / short MLYS into the catalyst window if you want to express a view that the market is overstating class-wide enthusiasm; AZN offers diversified downside protection while MLYS remains single-event fragile.
• For biotech event-vol portfolios, consider a long-vol structure around MLYS only if you can buy it after IV compresses; the expected move is still large, but edge improves materially when the market stops overpaying for the binary.
• Post-FDA approval: if MLYS gaps higher, sell a portion into the first 24-72 hours and reassess only after label details and payer commentary; the risk/reward shifts quickly from event alpha to commercialization execution.